Romiplostim
- Generic Name
- Romiplostim
- Brand Names
- Nplate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 267639-76-9
- Unique Ingredient Identifier
- GN5XU2DXKV
- Background
Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attache...
- Indication
Treatment of chronic immune thrombocytopenic purpura.
- Associated Conditions
- Chronic immune thrombocytopenia, Refractory immune thrombocytopenia
- Associated Therapies
- -
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 62
- Registration Number
- NCT01444417
- Locations
- 🇨🇦
Research Site, Quebec City, Quebec, Canada
Indirect Comparison Between Eltrombopag & Romiplostim
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01236014
Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 20
- Registration Number
- NCT00902018
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 72
- Registration Number
- NCT00303472
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
- First Posted Date
- 2005-07-04
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT00117143
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00111475
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath